Currently, it is generally believed that anti-PD-1/PD-L1 therapy may not benefit EGFR- or ALK fusion- mutated NSCLC patients and could even lead to severe adverse effects21,22,25. The gene discussed is ALK; the disease is non-small cell lung carcinoma.